Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.
- Dec 14, 2018Acquisition adds clinical stage novel immuno-oncology programs to Astellas' oncology pipeline
- Nov 28, 2018XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation- FLT3 mutation-positive AML is a life-threatening disease with significant unmet medical needs -
Nov 20, 2018Astellas US LLC and the Academy of Oncology Nurse & Patient Navigators (AONN+) Announce CollaborationNavigation Acuity Tool to be Developed by Astellas US LLC and AONN+
Nov 19, 2018Astellas to Present New Data on Gilteritinib in Multiple Populations of FLT3 Mutation-Positive Acute Myeloid Leukemia (AML) Patients at the 2018 American Society of Hematology (ASH) Annual Meeting- Abstracts include updated results from Phase 1 study of gilteritinib in patients with newly diagnosed AML -
- Oct 4, 2018Astellas Oncology Announces Grand Prize Winner of C3 Prize® at Union for International Cancer Control (UICC) World Cancer CongressThree innovators working to change cancer care awarded a combined $100,000 in grants following live pitch to a panel of judges that included celebrity entrepreneur Bill Rancic